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Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited disease of the heart muscle character-
ized by otherwise unexplained thickening of the left ventricle. Left ventricular outflow tract
(LVOT) obstruction is present in approximately two-thirds of patients and substantially
increases the risk of disease complications. Invasive treatment with septal myectomy or
alcohol septal ablation can improve symptoms and functional status, but currently available
drugs for reducing obstruction have pleiotropic effects and variable therapeutic responses.
New medical treatments with more targeted pharmacology are needed, but the lack of pre-
clinical animal models for HCM with LVOT obstruction has limited their development. HCM
is a common cause of heart failure in cats, and a subset exhibit systolic anterior motion of
the mitral valve leading to LVOT obstruction. MYK-461 is a recently-described, mechanisti-
cally novel small molecule that acts at the sarcomere to specifically inhibit contractility that
has been proposed as a treatment for HCM. Here, we use MYK-461 to test whether direct
reduction in contractility is sufficient to relieve LVOT obstruction in feline HCM. We evalu-
ated mixed-breed cats in a research colony derived from a Maine Coon/mixed-breed
founder with naturally-occurring HCM. By echocardiography, we identified five cats that
developed systolic anterior motion of the mitral valve and LVOT obstruction both at rest and
under anesthesia when provoked with an adrenergic agonist. An IV MYK-461 infusion and
echocardiography protocol was developed to serially assess contractility and LVOT gradient
at multiple MYK-461 concentrations. Treatment with MYK-461 reduced contractility, elimi-
nated systolic anterior motion of the mitral valve and relieved LVOT pressure gradients in an
exposure-dependent manner. Our findings provide proof of principle that acute reduction in
contractility with MYK-461 is sufficient to relieve LVOT obstruction. Further, these studies
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suggest that feline HCM will be a valuable translational model for the study of disease
pathology, particularly LVOT obstruction.
Introduction
Hypertrophic cardiomyopathy (HCM) is a heritable disease of the heart muscle characterized
by asymmetric thickening of the left ventricular walls not explained by another cardiac or sys-
temic disease. It is the most common heritable heart disease in humans with a prevalence of
one in 500 individuals [1]. Heart function in patients with HCM is characterized by hyperdy-
namic contraction [2] and impaired relaxation [3]. The clinical course is variable with some
patients experiencing minimal symptoms and others developing exertional dyspnea, heart fail-
ure, atrial fibrillation and stroke, or sudden cardiac death [4].
A predictor of adverse outcomes in HCM is the presence of left ventricular outflow tract
(LVOT) obstruction [5]. This phenomenon occurs when one or both of the mitral valve leaflets
contact the interventricular septum during systole (systolic anterior motion or SAM) and
impede bloodflow into the LVOT. As a result, a pressure gradient develops between the ventri-
cle and aorta, ventricular hypertrophy worsens and patients more frequently become symp-
tomatic. Although recognized as an important feature of HCM, the detailed mechanism of
SAM, and the relative contribution of distorted ventricular geometry, hypercontractility and
structural abnormalities of the mitral valve to generation of LVOT obstruction remain active
areas of investigation [6].
Approximately one-third of patients have LVOT obstruction at rest, and an additional one-
third develop obstruction only after provocation with exercise or other hemodynamic stressors
[7]. When this pathology is accompanied by persistent heart failure symptoms despite conven-
tional therapies, patients may be eligible for invasive septal reduction therapy. Patients with
severely obstructive (50 mmHg gradient), persistently symptomatic HCM who undergo
invasive septal reduction therapy (surgical myectomy or alcohol septal ablation) experience
improvement in symptoms, exercise capacity and prognosis in proportion to the resulting
LVOT gradient [8,9]. However, these interventions do not address the underlying molecular
pathology of disease. Currently available medical therapies for reducing obstruction (beta
blockers, calcium channel blockers and disopyramide) act through non-specific mechanisms,
achieve variable therapeutic responses and have pleiotropic pharmacological properties (effect-
ing inotropy, chronotropy, cardiac conduction, and vascular tone) that limit tolerability. None
of these pharmacologic therapies are demonstrated to improve the symptoms and functional
limitations associated with LVOT obstruction or to modify the natural history of disease [10].
New therapies with more targeted pharmacology are needed and could provide a medical
alternative to invasive therapies.
The development of new treatments has been limited in part by a lack of preclinical models
for HCM with obstructive physiology. Mouse models of HCM have been crucial in advancing
understanding of the biology and molecular biophysics of disease [11], but none develop SAM
or LVOT obstruction. In cats, HCM is recognized as a frequent cause of heart failure, disability
and death [12]. In a study of an unselected population of cats in a shelter, ~15% met criteria
for HCM [13]. Cats with HCM exhibit many structural and clinical features of the human dis-
ease, including myocyte hypertrophy, myofibrillar disarray, and fibrosis, as well as chronic
heart failure, an elevated risk for thromboembolism and sudden cardiac death [14]. There is
also a shared molecular mechanism, with two mutations in MYBPC3 (the most commonly
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mutated gene in human HCM) [15] implicated as disease-causing in cats [16]. LVOT obstruc-
tion caused by SAM is a feature of some feline HCM, although its prognostic value has not
been evaluated in a prospective study [17]. Cats may thus represent an appealing large-animal
system to study HCM pathophysiology—particularly LVOT obstruction—and potential thera-
peutic interventions.
Studies of tissues and purified proteins bearing mutations causing HCM are largely consis-
tent with the idea that HCM arises from a hypercontractile sarcomere [18]. Building on these
insights, a small molecule, MYK-461, that directly inhibits sarcomere force output to reduce
contractility was recently identified [19]. In contrast to existing medical therapies for HCM,
MYK-461 acts directly on myosin, the force generating protein in muscle and molecular
source of disease. In mouse models of HCM, early treatment with this molecule attenuates
ventricular hypertrophy, myofibrillar disarray and fibrosis, suggesting that reducing contractil-
ity at the sarcomere can modify the characteristic cellular and structural pathology of HCM.
However, it remains uncertain whether reducing sarcomere contractility is sufficient to correct
already established hemodynamic abnormalities of HCM including, importantly, LVOT
obstruction. Here, we describe studies in cats with HCM and dynamic LVOT obstruction to
test the hypothesis that a targeted reduction in contractility with a small molecule can acutely
eliminate SAM and reduce LVOT obstruction.
Methods
MYK-461 was synthesized at MyoKardia, Inc. For feline studies, 0.25 mg/kg MYK-461 was
prepared as sterile solution in PEG400/saline at 1/2 ratio for intravenous administration.
Animals
Care and handling of all animals was in accordance with the National Research Council Guide
for the Care and Use of Laboratory Animals using protocols approved by the Institutional Ani-
mal Care and Use Committee at University of California, Davis. Cats were obtained from a
research colony of Maine Coon/mixed breed cats with heritable HCM [14,20,21].
Experimental protocol
Five cats were selected for study that met previously established criteria [13] for feline HCM
and exhibited LVOT obstruction at rest under butorphanol and acepromazine sedation. All
cats received a combination of alfaxalone and midazolam for anesthetic induction, followed by
inhaled isoflurane and oxygen maintenance. Blood pressure was measured via an automated
blood pressure cuff at five-minute intervals with supplementary continuous monitoring by
arterial line when arterial access could be obtained. Following induction of anesthesia, a com-
plete baseline echocardiogram was performed (timepoint #1). Cats were then treated with
atropine 0.04 mg/kg IV, followed by an infusion of isoproterenol 0.04 μg/kg/min IV to elevate
heart rate back to pre-anesthetized values and induce the previously observed LVOT obstruc-
tion. After five to seven minutes, a stable heart rate of 200–220 bpm was reached and a com-
plete echocardiogram was performed (timepoint #2). At the completion of imaging, a ten-
minute intravenous infusion of MYK-461 (n = 5) at 0.3 mg/kg/hr IV was started (S1 Fig).
Focused echocardiography was performed after five minutes (timepoint #3). After ten min-
utes, the MYK-461 infusion rate was lowered to 0.12 mg/kg/hr IV, a blood sample was drawn
and an echocardiogram performed (timepoint #4). If ventricular function remained hypercon-
tractile or within normal limits by visual inspection, another blood sample was obtained and
the MYK-461infusion rate was increased to 0.36 mg/kg/hr IV for ten minutes. Focused echo-
cardiography was performed after five minutes (timepoint #5). After ten minutes, the MYK-
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461 infusion rate was lowered to 0.15 mg/kg/hr IV, a blood sample was drawn and an echocar-
diogram performed (timepoint #6). Following imaging, the isoproterenol infusion was discon-
tinued. When heart rate returned to baseline levels (five to seven minutes), a complete
echocardiogram was performed on MYK-461 alone (timepoint #7). Study drug was then dis-
continued, and animals were awakened, extubated and moved to recovery. Three of five cats
were available to return for a control arm of this experiment after a 6-week washout period.
The experiment was completed with identical methodology with the exception that MYK-461
was substituted for vehicle (control) at matched volumes/infusion rates.
Echocardiography
Complete two-dimensional, m-mode, color and spectral Doppler echocardiography was per-
formed from standard imaging planes in right and left lateral recumbency as previously
described [22]. Briefly, assessment of left ventricular hypertrophy was made from either m-
mode imaging in the right parasternal short axis view at the level of the papillary muscles or
two-dimensional imaging in the short or long axis plane at the same level. Segmental LV wall
measures in diastole that exceeded 6mm in the absence of other disease (systemic hyperten-
sion, hyperthyroidism) were considered consistent with HCM. Color flow and spectral Dopp-
ler as well as m-mode imaging was utilized to evaluate for systolic anterior motion of the
mitral valve and measure LVOT velocity as a surrogate marker of pressure gradient.
The initial echocardiogram for evaluating inclusion criteria was performed on awake,
sedated (butorphanol 0.25mg/kg and acepromazine 0.05mg/kg intramuscularly) cats.
Once selected and enrolled in this study, all cats were anesthetized for the remaining echo-
cardigoraphic assessments. Anesthesia was performed with alfaxalone and midazolam preme-
dication/induction then cats were intubated and maintained on inhaled isoflurane and
oxygen. A stable anesthetic plane was achieved prior to any drug intervention.
Focused echocardiography was obtained from the right parasternal short and long axis
imaging planes, where wall and chamber measures were obtained by both two-dimensional
and m-mode methods. Subcostal imaging was performed to provide superior alignment with
the left ventricular outflow tract and assess the left ventricular pressure gradient throughout
the study by continuous wave spectral Doppler.
MYK-461 Pharmacokinetics
MYK-461 pharmacokinetics was established in felines (n = 3) after a single dose IV bolus injec-
tion. Blood samples were collected 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72 and 336 hours post-dose
into K2-EDTA collection tubes. Plasma concentrations of MYK-461 were measured after
protein precipitation using a qualified LC-MS/MS method on AB Sciex Q-Trap API 5500
equipped with Thermo Fisher Scientific LC Aria LX2 with diverter valve. Samples were sepa-
rated on Kinetex 5u C18 100Å 30 x 2.1 mm analytical column (Phenomenex, Torrance, CA),
with gradient mobile phases consisting of 0.1% formic acid in water and 0.1% formic acid in
acetonitrile. Sample concentrations were determined from weighted linear regressions of peak
area ratios (peak areas of MYK-461 divided by peak areas of internal standard) versus nominal
concentrations of the calibration curve standards. All calibration standards and quality control
samples met ±15% accuracy acceptance criteria. The assay had a lower limit of quantitation of
2 ng/mL. Phoenix WinNonlin Software (Certara, Princeton, NJ) was used to calculate pharma-
cokinetc parameters, model and establish infusion protocol for pharmacodynamic study to
reach target pharmacodynamic effect.
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Results
A research colony of mixed breed (domestic short hair) cats with HCM was generated from a
single Maine Coon/mixed breed founder cat presenting with naturally-occurring disease
[14,21]. To identify cats in this colony with LVOT obstruction, we used echocardiography in
conscious animals to document hypertrophy (interventricular septum or left ventricular poste-
rior wall [diastole] > 0.6 cm) and blood flow acceleration in the LVOT consistent with
obstruction by continuous wave spectral Doppler, color Doppler, 2D and M-mode imaging
(S2 Fig). Five male cats ranging in age from 0.9 to 3.7 years met these criteria (Table 1). Three
of these cats exhibited more diffusely distributed hypertrophy with both left ventricular poste-
rior wall and interventricular septum measures (diastole) > 0.5 cm. The remaining two cats
had a more segmental pattern of hypertrophy with disproportionate thickening of the inter-
ventricular septum. Four cats demonstrated hyperdynamic left ventricular function (fractional
shortening (FS)> 55%), while one cat was within the normal range (35%< FS< 55%), consis-
tent with prior findings in both feline [17] and human HCM [23]. Three cats had enlarged left
atria (left atrial diameter / aortic root diameter > 1.5), indicative of chronically elevated left
ventricular filling pressures. These structural and functional parameters show that cats selected
for this study have morphologic signs of HCM with LVOT obstruction and chronic hemody-
namic abnormalities.
To characterize the dynamics of ventricular blood flow and outflow tract obstruction in
more detail, we performed complete echocardiograms in this cohort under anesthesia. Anes-
thesia was necessary to accurately measure LVOT velocities from subcostal views poorly toler-
ated by conscious cats and to maintain consistent hemodynamic parameters, but did alter
resting hemodynamics. During the baseline echo, heart rates in conscious cats ranged from
200–250 beats per minute (bpm). Anesthetized cats had slower heart rates (147 ± 20 bpm),
which were accompanied by a decrease in FS (52 ± 3%) (Fig 1A). Under these conditions,
LVOT obstruction and SAM were obliterated (Fig 1A–1C). From the earliest descriptions of
HCM, LVOT obstruction has been recognized as dynamic and often “intensified” by adrener-
gic agonists [24]. To reproduce the LVOT obstruction observed in conscious animals, anesthe-
tized cats were therefore treated with isoproterenol 0.04 mcg/kg/min IV, which elevated heart
rates to levels comparable to the conscious state (from 147 ± 20 bpm to 219 ± 13 bpm) and
increased FS (from 52 ± 3% to 77 ± 4%) (Fig 1A, S3 Fig). All five cats under study developed
SAM and evidence of LVOT obstruction (Fig 1A–1C). In one cat, SAM was accompanied by a
mild posteriorly-directed jet of mitral regurgitation (Fig 1D). These data indicate that this
cohort of cats has dynamic SAM and LVOT obstruction dependent on heart rate and
contractility.
Because conventional negative inotropes also directly modulate heart rate and/or vascular
tone, it has not been possible to pharmacologically isolate the contribution of changes in con-
tractility to the magnitude of LVOT obstruction. To address this question, we treated cats with
Table 1. Baseline demographic and echocardiographic characteristics.
ID Age (years) Sex IVSd (cm) LVPWd (cm) LVd (cm) LVs (cm) FS (%) LA/Ao
2011–26 3.7 M 0.66 0.47 0.98 0.43 56.4 1.35
2011–25 3.7 M 0.66 0.50 1.59 0.52 67.5 1.55
2011–17 3.9 M 0.72 0.57 1.13 0.39 65.6 1.52
2011–31 2.8 M 0.59 0.63 1.55 0.57 63.4 1.46
2011–44 0.9 M 0.63 0.60 1.27 0.76 40.6 1.53
Normal <0.60 <0.60 35–55 <1.5
doi:10.1371/journal.pone.0168407.t001
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MYK-461, a recently-described, mechanistically novel small molecule that inhibits sarcomere
contractility by directly binding β-cardiac myosin heavy chain and reducing its ability to pro-
ductively engage the thin filament [19]. Studies of MYK-461 in animals and isolated muscle-
fiber preparations have demonstrated concentration-dependent reductions in contractility
without changes to the intracellular calcium transient.
To observe regulation of contractility by MYK-461 in the feline heart, we administered
MYK-461 as an intravenous infusion and monitored heart function by echocardiography.
Compound infusion rates were calculated from dose-ranging pharmacokinetic studies of
MYK-461 to target up to 25% relative reduction in FS (see Detailed Methods). In three cats
available for follow up, studies were repeated with an infusion of vehicle alone after a washout
period of six weeks to ensure complete elimination of MYK-461.
We first compared FS prior to treatment (Fig 2A, timepoint #1) with that on only MYK-
461/vehicle (timepoint #7) (Fig 2A). Treatment with MYK-461 reduced FS from 52 ± 3% to
38 ± 7% (Fig 2B and 2C; p = 0.003 vs. vehicle, p = 0.01 vs. pre-treatment). The reduction in FS
Fig 1. Isoproterenol increases heart rate and contractility and induces dynamic LVOT obstruction in
cats with HCM. Treatment with isoproterenol 0.04 μg/kg/min IV (A) augments heart rate, fractional
shortening (FS) and LVOT gradient (n = 5, mean ± SD), (B) provokes mitral valve SAM and mitral/septal
contact (LV = left ventricle cavity, MV = anterior leaflet mitral valve), (C) induces an LVOT pressure gradient
(scale bar 0.5 m/s) and (D) mitral regurgitation.
doi:10.1371/journal.pone.0168407.g001
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corresponded to an increase in ventricular diameter at end-systole (0.67 cm vs 0.82 cm,
p = 0.03) with a stable end-diastolic diameter (1.40 cm vs. 1.34 cm, p = NS). To determine if
MYK-461 can reduce contractility in the presence of adrenergic stimulation, we compared FS
in cats receiving only isoproterenol 0.04 μg/kg/min IV (timepoint #2) with FS on both isopro-
terenol 0.04 μg/kg/min IV and MYK-461/vehicle IV. Treatment with MYK-461 reduced FS
from 81 ± 7% to 60 ± 13%, corresponding to a relative reduction of 25% (Fig 2D; p = 0.007 vs.
pre-461). To better define the exposure/response relationship, we measured FS and MYK-461
plasma concentrations at three additional times during the MYK-461 infusion (timepoints #3–
5, S2B Fig). Across all measurements there was a linear correlation between FS and MYK-461
plasma concentrations (Pearson’s r = 0.85; p<0.0001; Fig 2D and S1B Fig) with each 100 ng/
Fig 2. MYK-461 reduces contractility in feline HCM in an exposure-dependent manner. (A) Study
scheme depicting timing of echocardiograms (numbered) and administration of isoproterenol (iso) at constant
dose and MYK-461 or vehicle as a ramp infusion. Timepoints with asterisks correspond to blood draws to
measure plasma concentration of MYK-461. Timepoint 1: baseline following anesthesia; timepoint 2: stable
isoproterenol; timepoints 3–6: stable isoproterenol with increasing MYK-461 dose; timepoint 7: stable MYK-
461 dose without isoproterenol. (B) Decrease in contractility with MYK-461 treatment by M-mode
echocardiography. (C) Before and after plot of FS in response to treatment with MYK-461 (n = 5) or vehicle
(n = 3) in the absence of isoproterenol (*, p = 0.03 vs vehicle by unpaired t-test; **, p = 0.01 vs. pre-dose by
paired t-test). (D) Linear correlation of FS with MYK-461 plasma concentration for timepoints 2–6 in the
presence of isoproterenol (n = 3 cats, p<0.0001).
doi:10.1371/journal.pone.0168407.g002
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ml increase in MYK-461 concentration lowering FS by 4.9%. These data show that MYK-461
reduces contractility in cats with HCM, and can do so in the presence of adrenergic
stimulation.
We next investigated the effect of MYK-461 on provoked LVOT pressure gradients by
echocardiography. We compared hemodynamics in cats on isoproterenol alone (timepoint
#2) to cats on both isoproterenol and MYK-461 (timepoint #6). Treatment with MYK-461
eliminated SAM in 5/5 subjects, whereas SAM persisted in 3/3 subjects treated with vehicle
alone (Fig 3A; p = 0.018). Pressure gradients across the LVOT dropped to 11.1 ± 5.0 mmHg
with MYK-461 treatment, whereas vehicle treated cats maintained stable LVOT pressure gra-
dients (Fig 3B and 3C; p = 0.038 vs. vehicle, p = 0.0007 vs. pre-treatment). Despite the reduc-
tion in contractility and LVOT pressure gradient with MYK-461, systolic blood pressure
increased a modest amount from 96 ± 9 mmHg to 108 ± 8 mmHg (S3 Fig), suggesting a
Fig 3. Treatment with MYK-461 abolishes mitral valve SAM and reduces LVOT gradients in cats with
HCM. Treatment with MYK-461 abolishes (A) SAM and (B) LVOT obstruction induced by isoproterenol
treatment. (C) Before and after plot of LVOT pressure gradient for cats treated with isoproterenol 0.04 μg/kg/
min IV and either MYK-461 (n = 5) or vehicle (n = 3) (*, p = 0.038 vs. vehicle by unpaired t-test; **, p = 0.0007
vs. pre-dose by paired t-test). (D) Linear correlation of relative LVOT pressure gradient (normalized to values
prior to MYK-461 treatment) with the plasma concentration of MYK-461 at timepoints 2–6 (n = 3 cats,
p<0.0001).
doi:10.1371/journal.pone.0168407.g003
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hemodynamic benefit of relieving obstruction. To define the exposure/response relationship
for LVOT pressure gradient with MYK-461, we measured maximal pressure gradients in the
LVOT and MYK-461 plasma concentrations at three additional times during the MYK-
461infusion (timepoints #3–5). The relative pressure gradient across the LVOT correlated line-
arly with MYK-461 plasma exposures (r = 0.88; p<0.0001; Fig 3D), and each 100 ng/ml
increase in MYK-461 concentration reduced the gradient by 11% (2.3 mmHg). These data
demonstrate that specific reduction in contractility by selectively targeting myosin with MYK-
461 can relieve dynamic LVOT pressure gradients induced by adrenergic stimulation in cats
with HCM in an exposure-dependent manner.
Discussion
In this study, we identified a subset of cats from a research colony predisposed to HCM that
exhibit SAM and LVOT obstruction at rest. In detailed echocardiographic studies under anes-
thesia, SAM and LVOT obstruction could be provoked by adrenergic stimulation. MYK-461, a
small molecule that inhibits sarcomere contractility by selectively targeting myosin, reduced
FS in cats without affecting heart rate, and this was sufficient to acutely eliminate SAM and
relieve LVOT obstruction. These findings provide the first proof of principle that provokable
SAM and LVOT obstruction can be reduced by selectively reducing contractility using a novel
mechanistic class of direct sarcomere inhibitors. Because other available negative inotropes
have negative chronotropic effects (i.e. beta blockers and calcium channel blockers) or vasoac-
tivity (disopyramide), these data provide direct evidence that reduction in contractility is suffi-
cient to relieve LVOT obstruction.
Our data suggest that cats with HCM may serve as a model for provokable LVOT
obstruction. Mouse models have been invaluable for characterizing the genetics and cellular
pathology of HCM but have been limited by differences in physiology from human disease,
most prominently the absence of LVOT obstruction. Resting obstruction caused by SAM is
a feature of feline HCM in client-owned cats as well as in this research colony [17]. Because
of the hemodynamic effects of anesthesia, additional provocation was required to elicit
LVOT obstruction in this study. Isoproterenol was chosen because of its well-established
property of inducing gradients in HCM [24]. Although isoproterenol reliably augments
LVOT obstruction in HCM, previous studies in animals [25] and humans [26] have shown
that it does not induce SAM and LVOT outflow gradients in the normal ventricle. This
suggests that isoproterenol stimulation in cats with HCM and dynamic obstruction repre-
sents a distinct animal model to understand and develop therapeutics for this disease
pathophysiology.
Identification and treatment of LVOT obstruction is a cornerstone of therapy for patients
with HCM and symptoms of dyspnea and/or angina. The etiology of these symptoms is
incompletely understood, but they are thought to arise from a combination of interrelated
physiologic abnormalities including outflow obstruction, ischemia, diastolic dysfunction and
mitral regurgitation [27]. Current treatment guidelines recommend initiation of medicines
(beta blockers and calcium channel blockers) that can reduce heart rate and/or inotropy to
alleviate obstruction and reduce myocardial oxygen demand [28]. Despite the physiologic
rationale for these treatments, they have not shown clear benefit on symptoms or outcomes in
randomized trials [29]. Indeed, in one single center study of 509 patients with obstructive
HCM, 299 (58.7%) had persistent symptoms despite treatment with beta blockers and/or cal-
cium channel blockers [30]. These data suggest that non-selective negative inotropy and
chronotropy alone may not be sufficient to address the symptoms of HCM with LVOT
obstruction.
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A more definitive option for patients with symptomatic, obstructive HCM despite medical
therapy is septal reduction by surgical excision or alcohol ablation. Widening of the LVOT
with these interventions reduces LVOT pressure gradients with low procedural mortality and
morbidity, particularly with contemporary surgical techniques at high-volume centers [31].
Non-randomized, retrospective studies suggest that many patients have improved symptoms
and functional capacity as well as a potential improvement in long-term mortality [9,32].
However, a recent meta-analysis shows that symptomatic improvement is not uniform, with
up to 50% of patients not experiencing an improvement in NYHA functional class after septal
reduction [33]. This residual symptom burden suggests that eliminating the gradient alone
may not be sufficient to treat the disease. The molecular pathophysiology of HCM—which
ultimately gives rise to LVOT obstruction—also produces other abnormalities such as fibrosis
and diastolic dysfunction that are important sources of morbidity not addressed by septal
reduction [34].
Increasing understanding of the genetic basis of HCM has defined it as a disease of the sar-
comere. Mutations in genes encoding sarcomere proteins produce molecular biophysical
abnormalities that ultimately lead to the contractile dysfunction of the heart, fibrosis, hypertro-
phy and other downstream pathologies [18]. Based on these molecular insights, MYK-461 was
discovered in a screen for direct inhibitors of sarcomere activity [19]. Unlike beta blockers or
calcium channel blockers, sarcomere modulators act directly at the motor proteins to counter-
act the biochemical defect in HCM without affecting calcium handling or other aspects of
myocyte function. Sarcomere inhibitors could thus offer a targeted therapy for HCM that
more specifically addresses its underlying abnormalities. Furthermore, because perturbations
in motor function precipitate other manifestations of HCM (fibrosis, myofibrillar disarray,
arrhythmias), correcting the biochemical defect could also modify the cellular and molecular
pathology of disease.
Our study has several limitations. All studies of compound action were performed under
anesthesia, which alters multiple aspects of cardiovascular physiology, including contractility,
heart rate and vascular tone. Because of these changes, provocation by isoproterenol was nec-
essary to induce sustained LVOT pressure gradients despite the presence of LVOT obstruction
in conscious cats. Nevertheless, the pattern of SAM and LVOT obstruction under these condi-
tions was consistent with that found in conscious cats as well as in humans, suggesting that the
induced gradients could be a valid model to study the effects of modulating contractility. This
model may best reflect the LVOT gradients induced upon exercise provocation, which are
present in approximately one in three human HCM patients.
Thus, our studies provide proof of principle that a sarcomere inhibitor can acutely relieve
provocable LVOT gradients in cats with HCM. These data pave the way for chronic studies—
in animals and humans—under more physiologic conditions to test the durability of response
and the appearance of salutary remodeling and disease modification. Our results highlight the
value of companion animals in translational research and raise the potential of a novel thera-
peutic approach in HCM patients with LVOT obstruction.
Supporting Information
S1 Fig. Heart rate and blood pressure for cats on isoproterenol and treated with MYK-461
or vehicle. Treatment with MYK-461 does not alter heart rate but increases systolic blood
pressure (SBP) in cats on a stable dose of isoproterenol (p = 0.004), whereas SBP does not
change with vehicle treatment.
(EPS)
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S2 Fig. LVOT obstruction in a conscious cat with HCM. (A) Parasternal long axis image
with color Doppler in a conscious cat with HCM show acceleration of flow in the LVOT. (B)
Pulse wave Doppler profiles from the parasternal long axis view in a conscious cat with HCM
demonstrate elevated velocities in the LVOT (scale bar = 1 m/s).
(EPS)
S3 Fig. MYK-461 administration schedule and plasma concentrations in treated cats. (A)
Ramp infusion protocol for IV administration of MYK-461 (B) Plasma concentrations for cats
treated with MYK-461 (n = 3).
(EPS)
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